Lord Rennard

The Public Duty Costs Allowance (PDCA) was introduced to assist former Prime Ministers still active in public life. Payments are made only to meet the actual cost of continuing to fulfil public duties. The PDCA was exceptionally extended to the former Deputy Prime Minister, the Rt Hon Sir Nick Clegg from 2015-2019. No other former Deputy Prime Ministers claim the allowance.

The costs are a reimbursement of incurred expenses for necessary administrative costs arising from their special position in public life for example managing an office (staffing and administration costs); handling correspondence as a former Prime Minister; and support with visits and similar activities. The level of the limit is reviewed by the Prime Minister at the start of a Parliament and annually. Invoices are submitted to the Cabinet Office to cover relevant office and salary costs. PDCA claims are also subject to an annual audit by the National Audit Office.

The Cabinet Office does not hold a comprehensive record of claims made against the PDCA going back to 1991 when the allowance was established. However, I would refer the noble Lord to a written answer provided to him on 6 December 2022 by Baroness Neville-Rolfe, then Minister of State, (reference HL3763) which provides details of historical claims of PDCA.

Details of PDCA claims have been published in the Cabinet Office Annual Report and Accounts (ARA) since 2013-14. The written answer referred to above includes details of claims up to the financial year 2021-22. Details of claims for the financial years 2022-23 and 2023-24 are set out in Table 1 below, and can also be found in the relevant ARAs.

Table 1

In relation to the data provided in Table 1, it should be noted that The Rt Hon Lord David Cameron stopped receiving the allowance when he was appointed the Secretary of State for Foreign, Commonwealth and Development Affairs on 13 November 2023. The Rt Hon Boris Johnson was eligible to claim the Public Duty Cost Allowance, however no claims were received in 2022 to 2023. Due to 2022 to 2023 being the first year of set up, the Cabinet Office has agreed to reimburse these costs in 2023 to 2024. All future office costs are to be claimed in-year with claims received by 31 March. 2022 to 2023 office costs amounted to £67,083.

Details of the financial year 2024/25 will be published in the next Cabinet Office Annual Report and Accounts.

The Public Duty Costs Allowance (PDCA) was introduced to assist former Prime Ministers still active in public life. Payments are made only to meet the actual cost of continuing to fulfil public duties. The PDCA was exceptionally extended to the former Deputy Prime Minister, the Rt Hon Sir Nick Clegg from 2015-2019. No other former Deputy Prime Ministers claim the allowance.

The costs are a reimbursement of incurred expenses for necessary administrative costs arising from their special position in public life for example managing an office (staffing and administration costs); handling correspondence as a former Prime Minister; and support with visits and similar activities. The level of the limit is reviewed by the Prime Minister at the start of a Parliament and annually. Invoices are submitted to the Cabinet Office to cover relevant office and salary costs. PDCA claims are also subject to an annual audit by the National Audit Office.

The Cabinet Office does not hold a comprehensive record of claims made against the PDCA going back to 1991 when the allowance was established. However, I would refer the noble Lord to a written answer provided to him on 6 December 2022 by Baroness Neville-Rolfe, then Minister of State, (reference HL3763) which provides details of historical claims of PDCA.

Details of PDCA claims have been published in the Cabinet Office Annual Report and Accounts (ARA) since 2013-14. The written answer referred to above includes details of claims up to the financial year 2021-22. Details of claims for the financial years 2022-23 and 2023-24 are set out in Table 1 below, and can also be found in the relevant ARAs.

Table 1

In relation to the data provided in Table 1, it should be noted that The Rt Hon Lord David Cameron stopped receiving the allowance when he was appointed the Secretary of State for Foreign, Commonwealth and Development Affairs on 13 November 2023. The Rt Hon Boris Johnson was eligible to claim the Public Duty Cost Allowance, however no claims were received in 2022 to 2023. Due to 2022 to 2023 being the first year of set up, the Cabinet Office has agreed to reimburse these costs in 2023 to 2024. All future office costs are to be claimed in-year with claims received by 31 March. 2022 to 2023 office costs amounted to £67,083.

Details of the financial year 2024/25 will be published in the next Cabinet Office Annual Report and Accounts.

The Public Duty Costs Allowance (PDCA) was introduced to assist former Prime Ministers still active in public life. Payments are made only to meet the actual cost of continuing to fulfil public duties. The PDCA was exceptionally extended to the former Deputy Prime Minister, the Rt Hon Sir Nick Clegg from 2015-2019. No other former Deputy Prime Ministers claim the allowance.

The costs are a reimbursement of incurred expenses for necessary administrative costs arising from their special position in public life for example managing an office (staffing and administration costs); handling correspondence as a former Prime Minister; and support with visits and similar activities. The level of the limit is reviewed by the Prime Minister at the start of a Parliament and annually. Invoices are submitted to the Cabinet Office to cover relevant office and salary costs. PDCA claims are also subject to an annual audit by the National Audit Office.

The Cabinet Office does not hold a comprehensive record of claims made against the PDCA going back to 1991 when the allowance was established. However, I would refer the noble Lord to a written answer provided to him on 6 December 2022 by Baroness Neville-Rolfe, then Minister of State, (reference HL3763) which provides details of historical claims of PDCA.

Details of PDCA claims have been published in the Cabinet Office Annual Report and Accounts (ARA) since 2013-14. The written answer referred to above includes details of claims up to the financial year 2021-22. Details of claims for the financial years 2022-23 and 2023-24 are set out in Table 1 below, and can also be found in the relevant ARAs.

Table 1

In relation to the data provided in Table 1, it should be noted that The Rt Hon Lord David Cameron stopped receiving the allowance when he was appointed the Secretary of State for Foreign, Commonwealth and Development Affairs on 13 November 2023. The Rt Hon Boris Johnson was eligible to claim the Public Duty Cost Allowance, however no claims were received in 2022 to 2023. Due to 2022 to 2023 being the first year of set up, the Cabinet Office has agreed to reimburse these costs in 2023 to 2024. All future office costs are to be claimed in-year with claims received by 31 March. 2022 to 2023 office costs amounted to £67,083.

Details of the financial year 2024/25 will be published in the next Cabinet Office Annual Report and Accounts.

The Public Duty Costs Allowance (PDCA) was introduced to assist former Prime Ministers still active in public life. Payments are made only to meet the actual cost of continuing to fulfil public duties. The PDCA was exceptionally extended to the former Deputy Prime Minister, the Rt Hon Sir Nick Clegg from 2015-2019. No other former Deputy Prime Ministers claim the allowance.

The costs are a reimbursement of incurred expenses for necessary administrative costs arising from their special position in public life for example managing an office (staffing and administration costs); handling correspondence as a former Prime Minister; and support with visits and similar activities. The level of the limit is reviewed by the Prime Minister at the start of a Parliament and annually. Invoices are submitted to the Cabinet Office to cover relevant office and salary costs. PDCA claims are also subject to an annual audit by the National Audit Office.

The Cabinet Office does not hold a comprehensive record of claims made against the PDCA going back to 1991 when the allowance was established. However, I would refer the noble Lord to a written answer provided to him on 6 December 2022 by Baroness Neville-Rolfe, then Minister of State, (reference HL3763) which provides details of historical claims of PDCA.

Details of PDCA claims have been published in the Cabinet Office Annual Report and Accounts (ARA) since 2013-14. The written answer referred to above includes details of claims up to the financial year 2021-22. Details of claims for the financial years 2022-23 and 2023-24 are set out in Table 1 below, and can also be found in the relevant ARAs.

Table 1

In relation to the data provided in Table 1, it should be noted that The Rt Hon Lord David Cameron stopped receiving the allowance when he was appointed the Secretary of State for Foreign, Commonwealth and Development Affairs on 13 November 2023. The Rt Hon Boris Johnson was eligible to claim the Public Duty Cost Allowance, however no claims were received in 2022 to 2023. Due to 2022 to 2023 being the first year of set up, the Cabinet Office has agreed to reimburse these costs in 2023 to 2024. All future office costs are to be claimed in-year with claims received by 31 March. 2022 to 2023 office costs amounted to £67,083.

Details of the financial year 2024/25 will be published in the next Cabinet Office Annual Report and Accounts.

The National Audit Office is independent of the government.

Former Prime Ministers submit invoices to the Cabinet Office setting out their claims. This information is used by the Cabinet Office for auditing and assurance purposes and is made available to NAO.

Most of the claims are used to cover the salaries of the staff that work in the offices of the former Prime Ministers. These staff are not civil servants, and it would therefore not be appropriate for the Cabinet Office to publish any further detail.

The immigration white paper sets out a series of measures that will achieve a reduction in net migration, while maintaining the UK’s globally competitive offer to international students and making a significant contribution to growth by boosting our skills base.

This includes the commitment to explore the introduction of a levy on higher education (HE) provider income from international students, with proceeds to be reinvested in the domestic HE and skills system. The department will set out more details around the levy in the Autumn Budget.

Analysis of the potential impacts is based on the levy applying to English HE providers only. The department will fully consult all the devolved governments on the implementation of the international student levy.

The immigration white paper sets out a series of measures that will achieve a reduction in net migration, while maintaining the UK’s globally competitive offer to international students and making a significant contribution to growth by boosting our skills base.

This includes the commitment to explore the introduction of a levy on higher education (HE) provider income from international students, with proceeds to be reinvested in the domestic HE and skills system. The department will set out more details around the levy in the Autumn Budget.

Analysis of the potential impacts is based on the levy applying to English HE providers only. The department will fully consult all the devolved governments on the implementation of the international student levy.

The immigration white paper sets out a series of measures that will achieve a reduction in net migration, while maintaining the UK’s globally competitive offer to international students and making a significant contribution to growth by boosting our skills base.

This includes the commitment to explore the introduction of a levy on higher education (HE) provider income from international students, with proceeds to be reinvested in the domestic HE and skills system. The department will set out more details around the levy in the Autumn Budget.

Analysis of the potential impacts is based on the levy applying to English HE providers only. The department will fully consult all the devolved governments on the implementation of the international student levy.

The immigration white paper sets out a series of measures that will achieve a reduction in net migration, while maintaining the UK’s globally competitive offer to international students and making a significant contribution to growth by boosting our skills base.

This includes the commitment to explore the introduction of a levy on higher education (HE) provider income from international students, with proceeds to be reinvested in the domestic HE and skills system. The department will set out more details around the levy in the Autumn Budget.

Analysis of the potential impacts is based on the levy applying to English HE providers only. The department will fully consult all the devolved governments on the implementation of the international student levy.

The Government wants National Health Service patients in England to be able to benefit from rapid access to effective new medicines. The National Institute for Health and Care Excellence (NICE) evaluates all new licensed medicines and makes recommendations for the NHS on whether they should be routinely funded based on the evidence of clinical and cost effectiveness. NICE aims, wherever possible, to issue its recommendations close to the time of marketing authorisation to ensure that there is no gap between licensing and patient access to NICE recommended medicines. The 10-Year Health Plan and Life Science Sector Plan outline our commitments to speeding up access for NHS patients to new medicines through the introduction of a parallel marketing authorisation and NICE process.

NHS patients are able to benefit from access to promising new medicines through the Cancer Drugs Fund and Innovative Medicines Fund while further real-world evidence is collected on their use to inform a final NICE decision on whether they can be recommended for routine NHS funding.

The National Institute for Health and Care Excellence (NICE) develops its guidance independently and on the basis of an assessment of the available evidence, taking into account all health-related costs and benefits for patients and caregivers, including health outcomes, in line with its established methods and processes.

NICE does not take account of economic productivity in its assessments. It would involve valuing interventions differently based on the working status of the recipient population, which would be methodologically and ethically challenging and could systematically disadvantage certain groups including children, long-term sick and unemployed people, and could result in fewer treatments being recommended for these populations.

With the pace of innovation increasing, it is crucial now more than ever that the National Institute for Health and Care Excellence (NICE) is focused on the highest impact technologies.

The Rules-Based Pathway (RBP), recently announced in the 10-Year Health Plan and Life Sciences Sector Plan, will, for the first time, create a national pathway that guarantees funding for several rigorously selected transformative technologies each year, streamlining the route to adoption in the National Health Service for selected devices, diagnostics, and digital tools. This will give NICE a powerful lever to drive healthcare transformation and help to position the United Kingdom as a first-to-market location for cutting-edge technology.

NICE assessments have been carried out on diabetes technologies, including: insulin pumps; continuous glucose monitors; and most recently, hybrid closed loop systems. Diabetes technologies listed on Part IX of the NHS Drug Tariff are also subject to more frequent review.

The 2024 voluntary scheme for branded medicines pricing, access, and growth, which is an agreement between the Department, NHS England, and the Association of the British Pharmaceutical Industry, states that the standard NICE cost-effectiveness threshold will not change for the duration of the scheme, which ends in December 2028.

Under the current arrangements, NICE is able to recommend the majority of medicines it appraises for use on the NHS, with an approval rate of 84%.

The National Institute for Health and Care Excellence (NICE) will shortly be publishing its business plan, which will set out its priorities for 2025/26, following approval by the NICE Board. NICE’s priorities will include delivery of commitments outlined in the 10-Year Health Plan. These include:

- the adoption of a dynamic approach to appraisals that identifies where existing innovation should be retired and where technologies should be sequenced within the clinical pathway, to improve value and health outcomes;

- expanding NICE’s technology appraisal process to cover devices, diagnostics, and digital products, supported by the introduction of a rules-based pathway for HealthTech, to reduce variation in access to high-impact medical technologies; and

- alignment of NICE and the Medicines and Healthcare products Regulatory Agency processes, supported by information sharing and joint scientific advice, to speed up decision making and reduce the administrative burden for the system and industry, allowing new and innovative technologies to get to patients faster.

NHS England is working at a national level on behalf of the Department as part of a wider equality monitoring review programme. This review is exploring how best to update equality monitoring arrangements, including ethnicity categories, by reference to the protected characteristics outlined in the Equality Act 2010.

The National Diabetes Audit (NDA) is a major national clinical audit, which measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) clinical guidelines and NICE quality standards, in England and Wales. This includes NICE’s guidance on diabetes innovations like continuous glucose monitors and hybrid closed loop systems. The NDA is delivered by NHS England, in partnership with Diabetes UK.

The NDA consistently reveals inequalities in diabetes care and outcomes across different socioeconomic and demographic groups. People living in more deprived areas, younger individuals, and some ethnic minorities experience poorer access to care processes and treatment targets compared to their counterparts in less deprived areas and among older individuals.

The table below shows the number of contacts received by HMRC’s Fraud Reporting Gateway in relation to illicit tobacco. The data is only available for the last 7 years due to HMRC’s retention policies.

I refer the noble Lord to the answer I gave him on 4 June 2025 to question HL7693 reproduced below.

The Office for Budget Responsibility (OBR) publish details of their tobacco tax receipt forecast in the Economic and Fiscal Outlook (EFO) publication and forecast methodology page [1]. The OBR will provide further information on their analysis on request.

[1] https://obr.uk/forecasts-in-depth/tax-by-tax-spend-by-spend/tobacco-duties/

Like most businesses across the economy, tobacco producers and retailers are free to set prices for their products. Evidence suggests that close to 100% of tax increases, and in many cases more, is passed through to consumers through prices. How this is distributed across products is a matter for the individual firms.

The UK has some of the highest tobacco taxes in the world which have helped reduce smoking prevalence to 11.9%.

In order to protect the public health objectives of tobacco taxation the Minimum Excise Tax sets a minimum amount of duty collected on a pack of cigarettes. This discourages manufacturers from selling cheap cigarettes as it reduces the profitability of cigarettes sold at or below the trigger price of £13.59 for a pack of 20 cigarettes.

The Office for Budget Responsibility (OBR) publishes details of their tobacco tax receipt forecast in the Economic and Fiscal Outlook (EFO) publication and forecast methodology page. [1] The OBR provides further information on their analysis on request.

[1] https://obr.uk/forecasts-in-depth/tax-by-tax-spend-by-spend/tobacco-duties/

Like most businesses across the economy, tobacco producers and retailers are free to set prices for their products. Evidence suggests that close to 100% of tax increases, and in many cases more, is passed through to consumers through prices. How this is distributed across products is a matter for the individual firms.

The UK has some of the highest tobacco taxes in the world which have helped reduce smoking prevalence to 11.9%.

In order to protect the public health objectives of tobacco taxation the Minimum Excise Tax sets a minimum amount of duty collected on a pack of cigarettes. This discourages manufacturers from selling cheap cigarettes as it reduces the profitability of cigarettes sold at or below the trigger price of £13.59 for a pack of 20 cigarettes.